Clearpoint Neuro is trading at $16.10, up 6.13%, with no clear catalyst identified.
- No new company-specific announcement dated August 25, 2026 was identified; the latest listed release was its August 3, 2026 second-quarter report.
- The report lowered 2026 revenue guidance to $48.0–$52.0 million; later coverage highlighted a quarterly revenue miss, making it an unlikely explanation.
- Broader markets are modestly higher, but index moves show no clear global catalyst.